Study discovers protective genetic mutation for kidney disease

NewsGuard 100/100 Score

African Americans have long been known to be at increased risk of kidney disease due to a dangerous genetic mutation that creates a hole in the kidney cells, but Vanderbilt University Medical Center (VUMC) researchers have now discovered a protective genetic mutation that covers the hole to eliminate the risk.

The findings on the apolipoprotein L1 (APOL1) gene, published today in the Journal of the American Society of Nephrology, could have immediate and broad implications for kidney health because people with both the disease-causing and protective mutation are not at increased risk.

Our team discovered a different protective genetic mutation in APOL1 that counteracts the disease-causing mutation. We performed experimental studies and found that the harmful mutation creates a hole in kidney cells. Our protective mutation blocks the hole.

Alexander Bick, MD, PhD, senior author, Assistant Professor of Medicine, Division of Genetic Medicine

"There are medicines in late-stage clinical development that block the APOL1 hole just like our protective mutation does. Our study shows that these targeted personalized medicine drugs are likely to be a successful treatment strategy. Our results also identify a set of patients with both the harmful and protective APOL1 mutation who would not need this treatment," he said.

The large human genomic study looked at of 150,582 participants with African ancestry from the Million Veteran Program (MVP), BioVU (VUMC's de-identified DNA databank) and the All of US Research Program, the NIH's historic effort to collect and study data from 1 million or more people living in the United States to accelerate health research.

"The results of our study have immediate and broad implications for kidney health," said lead author Adriana Hung, MD, MPH, associate professor of Medicine, Division of Nephrology, and principal investigator for the kidney disease grant for the Million Veteran Program from the Department of Veterans Affairs. "Individuals with African descent and Latinos have a four-fold increase in the risk of progressing to end stage renal failure, which is partially explained by of APOL1 G1/G2 high risk variants."

"Additionally, kidney donors with APOL1 high risk variants are also at an increased risk of kidney disease, hence reducing the pool of kidney donors. Interventions to decrease these long-standing inequities in kidney health have been desperately needed," she said.

The authors are now evaluating the role of APOL1 high risk variants in different settings to understand the overall population that will benefit from pharmacologic inhibitors that mimic the genetic mutation by blocking the APOL1 pore formation and ion channel conduction.

"Our study represents an important step forward in precision nephrology," Hung said. "It is an extraordinary example of how human genomics studies translated into the discovery of new treatments."

Other Vanderbilt collaborators who participated in the study include Hua-Chang Chen, Zhihong Yu, Jefferson L. Triozzi, Lee Wheless, Otis D. Wilson, Trevor K. Thompson, Michael E. Matheny, Edward D. Siew, Ran Tao, and Cassianne Robinson-Cohen. MAZE therapeutics helped with the functional assays.

Source:
Journal reference:

Hung, A. M., et al. (2023) Genetic Inhibition of APOL1 Pore-Forming Function Prevents APOL1-Mediated Kidney Disease. Journal of the American Society of Nephrology. doi.org/10.1681/ASN.0000000000000219.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Gene therapy and glycoside drugs offer new hope for polycystic kidney disease treatment